Drug Profile
KP 624
Alternative Names: KP624Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Obio Pharmaceutical Holdings
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Undefined in USA
- 17 Mar 2009 Phase-I clinical trials in Undefined indication in USA (unspecified route)